Many pivotal studies were presented during the AACR 2018 Annual Meeting, held from April 14 to 18 in Chicago. MediPaper summarised the key papers from the AACR 2018, including the Keynote-089 (pembrolizumab plus chemotherapy in NSCLC) and the CheckMate 227 (nivolumab plus ipilimumab in TMB-high NSCLC) in non-small cell lung cancer (NSCLC). Do you know all the key results?
First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).
AACR 2018: First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).
AACR 2018: Frontline pembrolizumab plus chemotherapy in NSCLC reduces the risk of death by more than 50%. The Phase III KEYNOTE-189 trial combined pembrolizumab (Keytruda®) plus standard of care platinum-based chemotherapy in non-squamous non–small cell lung cancer (NSCLC) without EGFR or ALK genetic aberrations (NCT0278680)
bravajulia / 123RF Stock Photo
Hywards / 123RF Stock Photo
krishnacreations / 123RF Stock Photo